INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ).

GlobeNewsWire • Sep 1, 2026

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics NASDAQ: LENZ reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July rollout of national television advertising and a telehealth access option.

MarketBeat • Aug 11, 2026

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple monthly packs since launch, tracking to five packs annually VIZZ prescription growth accelerated with launch of telehealth channel in July 2026 Management to host conference call today, August 11, 2026, at 4:30 p.m. EDT SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the second quarter ended June 30, 2026, and recent corporate highlights.

GlobeNewsWire • Aug 11, 2026

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.53 per share a year ago.

Zacks Investment Research • Aug 11, 2026

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights.

GlobeNewsWire • Aug 4, 2026

Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline

LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 22, 2026

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals

GlobeNewsWire • Jul 6, 2026

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Zealand.

GlobeNewsWire • Jun 24, 2026

LENZ Therapeutics adds China partner for presbyopia drug VIZZ

LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China market, LENZ said.

Proactive Investors • Jun 8, 2026